{"id":28673,"date":"2014-08-19T09:09:16","date_gmt":"2014-08-19T13:09:16","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=28673"},"modified":"2014-08-19T09:09:16","modified_gmt":"2014-08-19T13:09:16","slug":"pfizer-inc-nysepfe-submits-new-drug-application-for-palbociclib","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-submits-new-drug-application-for-palbociclib-28673","title":{"rendered":"Pfizer Inc. (NYSE:PFE) Submits New Drug Application For Palbociclib"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 08\/19\/2014 (wallstreetpr) \u2013 Research-based global pharmaceutical firm <strong>Pfizer Inc. (NYSE:PFE)<\/strong> had submitted a New Drug Application or NDA to the Food and Drug Administration or the FDA for its palbociclib. The company seeks the FDA permission of palbociclib to be combined with letrozone for treating postmenopausal women of estrogen receptor positive or ER+, or negative human epidermal growth factor receptor 2 or HER2- advanced cancer.<\/p>\n<p style=\"text-align: justify;\"><strong>NDA Submission for Palbociclib<\/strong><\/p>\n<p style=\"text-align: justify;\">The <a href=\"https:\/\/finance.yahoo.com\/news\/pfizer-announces-submission-palbociclib-drug-120000031.html\" target=\"_blank\">company<\/a> disclosed that the NDA submission was based on the ultimate results of randomized, stage 2 trial of PALOMA-1 that compared palbociclib with letrozole and letrozole alone. In April 2013, FDA had accorded Breakthrough Therapy designation for Pfizer Inc. (NYSE:PFE)\u2019s Palbociclib for the first-line general treatment of women affected by advanced or metastatic ER+ or HER2- breast cancer. The regulator had assigned the designation based on the PALOMA-1 trial\u2019s interim data.<\/p>\n<p style=\"text-align: justify;\">The company stated that the medical regulator would review its NDA application during the 60-day filing review time in all respects before accepting it for filing. However, the pharmaceutical company believes that the submission was an important milestone and a possible advance for the treatment of advanced breast cancer.<\/p>\n<p style=\"text-align: justify;\"><strong>Palbociclib<\/strong><\/p>\n<p style=\"text-align: justify;\">Pfizer Inc. (NYSE:PFE) said that a palbociclib is an investigational oral agent, which selectively slowdown cyclin-dependent kinases or CDKs 4 and 6 to recover cell cycle control apart from block tumor cell proliferation. For the cancer, loss of cell cycle control was a hallmark. And CDK 4\/6 were over-activated in number of cancers thus driving a loss of proliferative control.<\/p>\n<p style=\"text-align: justify;\">The company indicated that CDK 4\/6 were important for many reasons including triggering cellular progression from the growth phase and its percolation connected with DNA replication. The company also said that palbociclib is not available in any market for any indication with FDA permission.<\/p>\n<p style=\"text-align: justify;\">Pfizer Inc. (NYSE:PFE) said that it had been working with global breast cancer experts and investigators to develop a strong development program for its palbociclib in HER2- or ER+ in different stages and treatment settings.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 08\/19\/2014 (wallstreetpr) \u2013 Research-based global pharmaceutical firm Pfizer Inc. (NYSE:PFE) had submitted a New Drug Application or NDA to the Food and Drug [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":25071,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[993,2745,3275],"stock_ticker":[],"class_list":["post-28673","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nysepfe","tag-pfizer-inc-nysepfe","tag-pfizer-inc","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pfizer Inc. (NYSE:PFE) Submits New Drug Application For Palbociclib  - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-submits-new-drug-application-for-palbociclib-28673\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer Inc. (NYSE:PFE) Submits New Drug Application For Palbociclib  - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 08\/19\/2014 (wallstreetpr) \u2013 Research-based global pharmaceutical firm Pfizer Inc. (NYSE:PFE) had submitted a New Drug Application or NDA to the Food and Drug [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-submits-new-drug-application-for-palbociclib-28673\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-08-19T13:09:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Pfizer-Inc..jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"284\" \/>\n\t<meta property=\"og:image:height\" content=\"177\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Greg Folin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Greg Folin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-submits-new-drug-application-for-palbociclib-28673#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-submits-new-drug-application-for-palbociclib-28673\"},\"author\":{\"name\":\"Greg Folin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\"},\"headline\":\"Pfizer Inc. (NYSE:PFE) Submits New Drug Application For Palbociclib\",\"datePublished\":\"2014-08-19T13:09:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-submits-new-drug-application-for-palbociclib-28673\"},\"wordCount\":342,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-submits-new-drug-application-for-palbociclib-28673#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Pfizer-Inc..jpg\",\"keywords\":[\"NYSE:PFE\",\"Pfizer Inc (NYSE:PFE)\",\"Pfizer Inc.\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-submits-new-drug-application-for-palbociclib-28673#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-submits-new-drug-application-for-palbociclib-28673\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-submits-new-drug-application-for-palbociclib-28673\",\"name\":\"Pfizer Inc. (NYSE:PFE) Submits New Drug Application For Palbociclib - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-submits-new-drug-application-for-palbociclib-28673#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-submits-new-drug-application-for-palbociclib-28673#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Pfizer-Inc..jpg\",\"datePublished\":\"2014-08-19T13:09:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-submits-new-drug-application-for-palbociclib-28673#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-submits-new-drug-application-for-palbociclib-28673\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-submits-new-drug-application-for-palbociclib-28673#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Pfizer-Inc..jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Pfizer-Inc..jpg\",\"width\":284,\"height\":177},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-submits-new-drug-application-for-palbociclib-28673#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer Inc. (NYSE:PFE) Submits New Drug Application For Palbociclib\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\",\"name\":\"Greg Folin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"caption\":\"Greg Folin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pfizer Inc. (NYSE:PFE) Submits New Drug Application For Palbociclib  - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-submits-new-drug-application-for-palbociclib-28673","og_locale":"en_US","og_type":"article","og_title":"Pfizer Inc. (NYSE:PFE) Submits New Drug Application For Palbociclib  - Wall Street PR","og_description":"Boston, MA 08\/19\/2014 (wallstreetpr) \u2013 Research-based global pharmaceutical firm Pfizer Inc. (NYSE:PFE) had submitted a New Drug Application or NDA to the Food and Drug [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-submits-new-drug-application-for-palbociclib-28673","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-08-19T13:09:16+00:00","og_image":[{"width":284,"height":177,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Pfizer-Inc..jpg","type":"image\/jpeg"}],"author":"Greg Folin","twitter_misc":{"Written by":"Greg Folin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-submits-new-drug-application-for-palbociclib-28673#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-submits-new-drug-application-for-palbociclib-28673"},"author":{"name":"Greg Folin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e"},"headline":"Pfizer Inc. (NYSE:PFE) Submits New Drug Application For Palbociclib","datePublished":"2014-08-19T13:09:16+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-submits-new-drug-application-for-palbociclib-28673"},"wordCount":342,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-submits-new-drug-application-for-palbociclib-28673#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Pfizer-Inc..jpg","keywords":["NYSE:PFE","Pfizer Inc (NYSE:PFE)","Pfizer Inc."],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-submits-new-drug-application-for-palbociclib-28673#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-submits-new-drug-application-for-palbociclib-28673","url":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-submits-new-drug-application-for-palbociclib-28673","name":"Pfizer Inc. (NYSE:PFE) Submits New Drug Application For Palbociclib - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-submits-new-drug-application-for-palbociclib-28673#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-submits-new-drug-application-for-palbociclib-28673#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Pfizer-Inc..jpg","datePublished":"2014-08-19T13:09:16+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-submits-new-drug-application-for-palbociclib-28673#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-submits-new-drug-application-for-palbociclib-28673"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-submits-new-drug-application-for-palbociclib-28673#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Pfizer-Inc..jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/06\/Pfizer-Inc..jpg","width":284,"height":177},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/pfizer-inc-nysepfe-submits-new-drug-application-for-palbociclib-28673#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Pfizer Inc. (NYSE:PFE) Submits New Drug Application For Palbociclib"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e","name":"Greg Folin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","caption":"Greg Folin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/28673","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=28673"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/28673\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/25071"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=28673"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=28673"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=28673"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=28673"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}